WE CLAIM:

1. An aqueous solution of risperidone, the aqueous solution comprising:

water;

a therapeutically effective amount of risperidone or a pharmaceutically acceptable free risperidone base or acid addition salt of risperidone;

one or more polyhydric alcohols; and

one or more buffering agents configured to maintain the pH in the range of about 3 to about 4..

2. The aqueous solution of claim 1, wherein the addition salt is selected from one or more of salts of risperidone with inorganic acids comprising hydrochloric, hydrobromic, sulfuric, nitric, and phosphoric acids; or organic acids comprising acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methane-sulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, and pamoic acids.

3. The aqueous solution of claim 1 wherein the one or more polyhydric alcohols comprises one or more of monosaccharides, disaccharides and sugars.

4. The aqueous solution of claim 3 wherein the monosaccharide comprises one or both of glucose (dextrose) and fructose (levulose).

5. The aqueous solution of claim 3 wherein the disaccharide comprises one or more of sucrose, lactose, maltose and cellobiose.

6. The aqueous solution of claim 3 wherein the disaccharide comprises sucrose.

7. The aqueous solution of claim 3 wherein the sugars comprise one or more of ribose, glycerine, sorbitol, xylitol, maltitol, erythritol, inositol, lactitol monohydrate, propylene glycol, galactose, mannose, xylose, rhamnose, glutaraldehyde, invert sugars, mannitol, polyethylene glycol and glycerol.

8. The aqueous solution of claim 3 wherein the sugar comprises sorbitol.

9. The aqueous solution of claim 1 wherein the aqueous solution further comprises an antioxidant.

10. The aqueous solution of claim 9 wherein the antioxidant comprises one or more of antioxidants, reducing agents and antioxidant synergist.

11. The aqueous solution of claim 10 wherein the antioxidants comprises one or more of acetylcysteine, alpha tocopherol acetate, d- alpha tocopherol, dl- alpha tocopherol, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), cysteine, cysteine hydrochloride and propyl gallate.

12. The aqueous solution of claim 10 wherein the reducing agent comprises one or more of ascorbic acid, calcium ascorbate, calcium bisulphite, calcium sulphite, ascorbic acid, isoascorbic acid, potassium metabisulphite, sodium ascorbate, sodium bisulphite, sodium metabisulphite, sodium sulphite, sodium thiosulphate and thioglycerol.

13. The aqueous solution of claim 10 wherein the antioxidant synergist comprises one or more of citric acid, edetic acid (EDTA) and its salts, hydroxyquinoline sulphate, phosphoric acid, sodium citrate and tartaric acid.

14. The aqueous solution of claim 1 wherein the solution further comprises one or more pharmaceutically acceptable additives.

15. The aqueous solution of claim 14 wherein the one or more pharmaceutically acceptable additives comprise one or more of preservatives, solubilizers, viscosity enhancing agents, colors and flavors.

16. The aqueous solution of claim 15 wherein the preservative comprises one or more of benzoic acid, sorbic acid, methyl paraben or salts thereof, propyl paraben or salts thereof, benzyl alcohol and benzylalkonium chloride.

17. The aqueous solution of claim 1 wherein the buffering agent comprises an acid-base combination.

18. The aqueous solution of claim 17 wherein the acid comprises one or more of succinic, tartaric, lactic, or citric acid and base is sodium hydroxide or disodium hydrogen phosphate.

19. The aqueous solution of claim 17 wherein the acid is tartaric acid and base is sodium hydroxide.

20. The aqueous solution of claim 15 wherein the flavors comprise one or more of vanilla, cherry, raspberry, black currant, strawberry, caramel chocolate, Mint Cool and Fantasy flavors.

21. A process for the preparation of an aqueous solution, the process comprising:

mixing water, a therapeutically effective amount of risperidone or a pharmaceutically acceptable free risperidone base or acid addition salt of risperidone, one or more polyhydric alcohols; and one or more buffering agents configured to maintain the pH in the range of about 3 to about 4.

22. A method for the management or treatment of the manifestations of psychotic disorders in a mammal, the method comprising administering an aqueous solution comprising water; a therapeutically effective amount of risperidone or a pharmaceutically acceptable free risperidone base or acid addition salt of risperidone; one or more polyhydric alcohols; and one or more buffering agents configured to maintain the pH in the range of about 3 to about 4.